Therefore, we inferred from these findings that increased CALR and PDIA3 in NSCLC are considered as antigen markers of immunogenicity, which are able to mount an immune response, similar to PDIA3 in colorectal cancer [31], facilitating anticancer immunosurveillance and contributing to better clinical outcome. This evidence concerns the gene CALR and colorectal cancer.